US FDA warns public of fraudulent stem cell schemes
This article was originally published in Clinica
Executive Summary
US regulators have warned consumers about fraudsters peddling potentially dangerous and ineffective stem cell treatments. They noted that only one stem cell product is approved by the US FDA – Hemacord, a haematopoietic progenitor cell product derived from cord blood, which is manufactured by the New York Blood Center and used for specified indications in patients with disorders affecting the body’s blood-forming system.